Influence of G-protein b-Polypeptide 3 XXXX Polymorphism on Antihypertensive Response to @entity9887 and @entity3591 in Chinese @entity1 .

@entity1 @entity101 @entity39036 @entity14644 @entity14643 @entity13519 @entity3591 @entity9887
BACKGROUND: G-protein b-polypeptide 3 ( @entity14644 ) is a b subunit isoform of G-protein that plays important role in signal transduction of membrane G-protein coupled receptors (GPCRs). The @entity14644 splice variant @entity14643 ( @entity39036 ) is associated with risk for essential @entity101 (EH) and efficacy of therapeutic drugs targeting GPCRs. It is unknown whether the polymorphism is associated with blood pressure (BP) response to @entity9887 or @entity3591 , two widely prescribed antihypertensive drugs. METHODS: A total of 93 subjects initially diagnosed as EH were recruited and underwent a 4-week treatment with @entity9887 (42 @entity1 ) or @entity3591 (51 @entity1 ) monotherapy. Both baseline and after-treatment BP were measured. @entity14644 @entity14643 polymorphism was genotyped by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: Baseline @entity13519 (DBP) were comparable among @entity14643 genotypes in both @entity9887 and @entity3591 treatment groups. @entity1 with the CT or TT genotypes showed significantly lower body mass index (BMI) as compared with CC homozygotes in both groups (P < 0.05, respectively). @entity14644 825TT homozygotes showed significantly higher after-treatment DBP and mean arterial pressure (MAP) than those carrying at least one 825C allele (P < 0.01) in the @entity9887 treatment group. No difference in after-treatment @entity13519 , DBP, and MAP levels among @entity14643 genotypes was observed in the @entity3591 treatment group. No significant difference in absolute changes in BP levels was observed among the genotypes in either treatment group. CONCLUSION: The @entity14644 @entity14643 splice variant is associated with the DBP-lowering effect of @entity9887 but not @entity3591 in Chinese EH @entity1 .
